On Invalid Date, Pasithea Therapeutics (NASDAQ: KTTA) reported Q1 2023 earnings per share (EPS) of -$0.14, up 100% year over year. Total Pasithea Therapeutics earnings for the quarter were -$3.54 million. In the same quarter last year, Pasithea Therapeutics's earnings per share (EPS) was -$0.07.
As of Q2 2023, Pasithea Therapeutics's earnings has grown year over year. Pasithea Therapeutics's earnings in the past year totalled -$15.90 million.
What is KTTA's earnings date?
Pasithea Therapeutics's earnings date is Invalid Date. Add KTTA to your watchlist to be reminded of KTTA's next earnings announcement.
What was KTTA's revenue last quarter?
On Invalid Date, Pasithea Therapeutics (NASDAQ: KTTA) reported Q1 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Pasithea Therapeutics's revenue was $0.00.
What was KTTA's revenue growth in the past year?
As of Q2 2023, Pasithea Therapeutics's revenue has grown 3,039.7% year over year. This is 2,970.48 percentage points higher than the US Biotechnology industry revenue growth rate of 69.21%. Pasithea Therapeutics's revenue in the past year totalled $472.90 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.